Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2387 | Mindfulness Meditation Wiki | 0.58 |
| drug2780 | PLACEBO GROUP Wiki | 0.58 |
| drug993 | Community Referral as appropriate Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003192 | Compulsive Behavior NIH | 0.58 |
| D009771 | Obsessive-Compulsive Disorder NIH | 0.41 |
| D001010 | Anxiety, Separation NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000072861 | Phobia, Social NIH | 0.41 |
| D003193 | Compulsive Personality Disorder NIH | 0.41 |
| D001416 | Back Pain NIH | 0.41 |
| D017116 | Low Back Pain NIH | 0.41 |
| D000379 | Agoraphobia NIH | 0.41 |
| D010698 | Phobic Disorders NIH | 0.41 |
| D016584 | Panic Disorder NIH | 0.29 |
| D004194 | Disease NIH | 0.09 |
| D001008 | Anxiety Disorders NIH | 0.08 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0003418 | Back pain HPO | 0.41 |
| HP:0000756 | Agoraphobia HPO | 0.41 |
| HP:0003419 | Low back pain HPO | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000722 | Obsessive-compulsive behavior HPO | 0.33 |
Navigate: Correlations HPO
There are 3 clinical trials
Anxiety is among the most prevalent, costly and disabling illnesses and tends emerge early in childhood. Cognitive behavioral therapy (CBT) is the first-line treatment for early life anxiety, but as many as 40% of young patients who receive CBT fail to get better. The proposed study will examine brain changes marking positive response to CBT for anxiety and how these changes may differ in children compared adolescents. By helping us to understand how CBT works, this study will pave the way for new treatments to stop anxiety early.
Description: Pre- to post-CBT changes in functional, connectivity and structural MRI measures of brain networks relevant for anxiety. Brain regions include the amygdala, anterior insula, dorsal anterior cingulate cortex (dACC) and ventrolateral prefrontal cortex (vlPFC). Functional activation and connectivity of these brain regions are assessed using simple computer tasks performed during MRI scanning. Tasks engage threat reactivity, self-regulatory control and the interaction of these processes. Structural connections between regions will be measured using a MRI technique that measures water diffusion in the brain.
Measure: Brain function/structure as assessed by Magnetic Resonance Imaging scans Time: Baseline and 12-weeksDescription: The Pediatric Anxiety Rating Scale (PARS) is a clinician-administered assessment to rate the severity of anxiety symptoms associated with common DSM-V anxiety disorders (social phobia, separation anxiety disorder, and generalized anxiety disorder) in children. The investigators are looking for decreases in anxiety severity ratings from pre- to post-treatment.
Measure: Pediatric Anxiety Rating Scale Time: weeks 0, 3, 6, 9, 12Chronic low back pain (CLBP) has no known effective treatment. While often treated with long-term opioid therapy, opioids do not work well for many patients and can cause serious side effects, including addiction, poorer mental health, and overdose death. Even when paired with a standard-of-care cognitive behavioral therapy (CBT), results are limited. Patients, families and clinicians are very interested in using alternative treatments for CLBP, especially complementary and integrative treatments such as mindfulness meditation (MM). MM helps train the mind to bring non-judgmental and accepting attention to present-moment experiences such as pain. MM offers an active and safe self-care approach to chronic pain that contrasts with the passive and potentially harmful nature of opioid treatment, and may prove more effective than CBT in helping improve health and well-being, and reduce reliance on opioids in adults with opioid-treated CLBP. Although this hypothesis is supported by early research, including a pilot study by the Principal Investigator, evidence on MM's effectiveness in this population is inconclusive, presenting a critical knowledge gap. With input from patients, family members, and clinicians, the Investigators have designed a study to address this gap and propose a clinical trial that will compare the effectiveness of MM to standard-of-care CBT in opioid-treated CLBP. Based on the existing research, it is hypothesized that MM training will lead to a larger reduction in pain intensity, increase in physical function, improvement in quality of life, and decrease in daily opioid dose, as compared to CBT training, with benefits of MM especially notable in adults with worse mood, anxiety or unhealthy opioid-use behaviors who often experience more severe symptoms of CLBP and less improvement in response to existing therapies. To test these hypotheses, 766 adults with opioid-treated CLBP will be randomly assigned into one of two 8-week treatment groups: MM (383 participants) that will receive the MM training or CBT (383 participants) that will receive the CBT training. Due to the COVID-19 pandemic-related restrictions, the study protocol was modified in October 2020 so that the study can be completed virtually. The effectiveness of MM versus CBT will be assessed over a 12-month period with patient-reported measures, recommended by experts and endorsed by our stakeholder partners, including patients with opioid-treated CLBP, their families and clinicians.
Description: 4 pain severity items from the Brief Pain Inventory
Measure: Pain Intensity Time: Baseline to 12 monthsDescription: 10-item Oswestry Disability Index
Measure: Physical Function Time: Baseline to 12 monthsDescription: 12-item Short Form-12
Measure: Quality of Life Time: Baseline to 12 monthsDescription: Timeline Followback Method (morphine-equivalent dose [mg/day] over the prior 14 days)
Measure: Daily Opioid Dose Time: Baseline to 12 monthsDescription: 14-item Hospital Anxiety and Depression Scale
Measure: Depression Symptom Severity Time: Baseline to 12 monthsDescription: 14-item Hospital Anxiety and Depression Scale
Measure: Anxiety Symptom Severity Time: Baseline to 12 monthsDescription: 17-item Current Opioid Misuse Measure
Measure: Opioid Use Behaviors Time: Baseline to 12 monthsDescription: 8-item Opioid Compliance Checklist
Measure: Opioid Medication Compliance Time: Baseline to 12 monthsThis study will use magnetic resonance imaging (MRI) to assess the function and structure of overlapping task control circuits in children with a range of Obsessive-Compulsive symptoms (OCS). The functioning of task control circuits will be assessed using the well-validated Multisource interference task (MSIT). This study will also assess functional and anatomical connectivity within task control circuits in the same children, and determine whether disturbances in these overlapping circuits are associated with Obsessive-Compulsive Disorder (OCD) symptom severity. Behavioral measures will be administered to further assess regulatory, learning and memory functions. Children with OCD will then be offered a standard course of cognitive behavioral therapy (CBT) before rescanning (along with age-and gender-matched control participants) in order to assess how these circuits may change with treatment. Children with subclinical OC symptoms will be offered referral for treatment on an as-needed basis. In addition, de-identified data may be used in the future to conduct secondary data analyses. As more about OC symptoms and neurobiological mechanisms of interest in the current study are understood, data may be used to answer questions beyond those described in this protocol. All study procedures will be conducted on-site at Columbia University/the New York State Psychiatric Institute (New York, NY) and the University of Michigan's outpatient Child and Adolescent Psychiatry (Ann Arbor, Michigan).
Description: Child Yale-Brown Obsessive Compulsive Scale (CYBOCS) is scored on a scale of 0 to 40, with 40 being the most severe.
Measure: Child Yale-Brown Obsessive Compulsive Scale Time: approximately 1 hourAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports